bioRxivPhysiology
PCSK9 inhibition protects mice from food allergy
V. Lorant, M. Klein, D. Garcon, T. Sotin, S. Frey, M.-A. Cheminant, A. Ayer, M. Croyal, L. Flet, L. Colas, B. Cariou, G. Bouchaud, C. Le May
Abstract
The Proprotein Convertase Subtilisin Kexin of type 9 (PCSK9) has been identified in 2003 as the third gene involved in familial hypercholesterolemia. PCSK9 binds to the membrane low-density lipoprotein receptor (LDLR) and promotes its cellular internalization and lysosomal degradation. Beyond this canonical role, PCSK9 was recently described to be involved in several immune responses. However, to date, the contribution of PCSK9 in food allergy remains unknown. Here, we showed that Pcsk9 deficiency or pharmacological inhibition of circulating PCSK9 with a specific monoclonal antibody (m-Ab) protected mice against symptoms of gliadin-induced-food allergy, such as increased intestinal transit time and ear oedema. Furthermore, specific PCSK9 inhibition during the elicitation steps of allergic process was sufficient to ensure anti-allergic effects in mice. Interestingly, the protective effect of PCSK9 inhibition against food allergy symptoms was independent of the LDLR as PCSK9 inhibitors remained effective in Ldlr deficient mice. In vitro, we showed that recombinant gain of function PCSK9 (PCSK9 D374Y) increased the percentage of mature bone marrow derived dendritic cells (BMDCs), promoted naive T cell proliferation and potentiated the gliadin induced basophils degranulation. Altogether, our data demonstrate that PCSK9 inhibition is protective against gliadin induced food allergy in a LDLR-independent manner.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels
Carole Fruchart‐Gaillard, Ali Ben Djoudi Ouadda, … Nabil Georges Seidah·Molecular MetabolismPeer-reviewed·Dec 22, 2022
- Alirocumab attenuated plaque inflammation and PCSK9-induced proinflammatory signalling in M1 macrophages independently of lipid lowering
Cristina Espadas, Manuel Soto‐Catalán, … Oscar Lorenzo·BiomoleculesPeer-reviewed·Mar 6, 2026
- Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9
Yating Wang, Brea Tinsley, … Lale Özcan·Journal of Lipid ResearchPeer-reviewed·Feb 2, 2024
- A transient amphipathic helix in the PCSK9 prodomain facilitates low-density lipoprotein binding
Samantha K. Sarkar, Alexander C. Y. Foo, … Thomas A. Lagace·Journal of Biological ChemistryPeer-reviewed·Jan 16, 2020
- Cell-associated, Heparin-like Molecules Modulate the Ability of LDL to Regulate PCSK9 Uptake
A. M. Galvan, J. S. Chorba·bioRxiv·May 23, 2018
- Pyrroloquinoline Quinone inhibits PCSK9, augments LDLR recycling and enhances the effect of atorvastatin
K. V. Devasani, A. Majumdar, … R. Kaul·bioRxiv·Mar 20, 2022